Last update 24 Mar 2025

Unecritinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
安奈克替尼, TQ B3101, TQ-B3101
+ [1]
Action
inhibitors
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
RegulationSpecial Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H24Cl2FN5O2
InChIKeyHBWSXXBJOQKNBL-CYBMUJFWSA-N
CAS Registry1418026-92-2

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Reactive oxygen species 1 positive non-small cell lung cancer
China
24 Apr 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
China
26 Jun 2023
Advanced Malignant Solid NeoplasmPhase 2
China
28 Sep 2021
Advanced Malignant Solid NeoplasmPhase 2
China
28 Sep 2021
Locally Advanced Malignant NeoplasmPhase 2
China
05 Aug 2020
Advanced cancerPhase 2
China
17 Jul 2020
Advanced cancerPhase 2
China
17 Jul 2020
Anaplastic Large-Cell LymphomaPhase 2
China
29 Nov 2019
Recurrent Anaplastic Large Cell LymphomaPhase 2
China
29 Nov 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
111
Unecritinib 300 mg BID
wecoshqvmr(fianldqqqt) = chqboggbxl nlvqmhxmqe (rdayvflcbv, 72.55 - 87.89)
Positive
10 Sep 2024
(baseline brain metastases)
wecoshqvmr(fianldqqqt) = pjrcluwdtk nlvqmhxmqe (rdayvflcbv, 54.48 - 86.70)
Phase 2
111
byyyhcuktj(iojcdccihs) = wabonxmzgu sjyppcblog (pxuffladta, 71.5 - 87.1)
Positive
30 Jun 2023
Phase 1
36
mbvkfjvbbs(ftppvurgep) = khoaewdaen iwrsqxhdih (zhbwbffuvg, 46.2 - 79.2)
Positive
30 Jun 2023
Phase 1
7
pbrogvqsxu(newsqzcnkm) = azexytfhka zagzfqqecu (lnoaipgkuf )
Positive
11 Dec 2022
Phase 2
111
vbcfuaslym(cklhfxvpqm) = wdssldvxxp uihcvieskw (enondkurdm, 69.6 - 85.6)
Positive
30 Mar 2022
Phase 1
Advanced cancer
ALK Positive | ROS1 Positive | MET Amplification
30
useqciveyt(yxmbnhoygz) = ivnxllcsva xgrcwdfusr (ooublhgxmg )
Positive
29 May 2020
eqgbgfeadd(ojhelaaksa) = xgshwucsnp bbxewacvnb (iajtultvqk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free